Phase 2 Study of Venetoclax Plus Rituximab or Randomized Ven Plus Bendamustine plus Rituximab (BR) Versus BR in Patients with Relapsed/Refractory Follicular Lymphoma: Interim Data

被引：8
|
作者：
Zinzani, Pier Luigi [1 ]
Topp, Max S. [2 ]
Yuen, Sam L. S. [3 ]
Rusconi, Chiara [4 ]
Fleury, Isabelle [5 ,6 ]
Pro, Barbara [7 ]
Gritti, Giuseppe [8 ]
Crump, Michael [9 ]
Hsu, Wanling [10 ]
Punnoose, Elizabeth A. [10 ]
Hilger, James [10 ]
Mobasher, Mehrdad [10 ]
Hiddermann, Wolfgang [11 ]
机构：
[1] Univ Bologna, Inst Hematol LEA Seragnoli, Bologna, Italy
[2] Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany
[3] Calvary Mater Newcastle, Dept Haematol, Newcastle, NSW, Australia
[4] Osped Niguarda Ca Granda, Div Hematol, Milan, Italy
[5] Maisonneuve Rosemont Hosp, Dept Hematol, Montreal, PQ, Canada
[6] Univ Montreal, Montreal, PQ, Canada
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL USA
[8] Osped Papa Giovanni XXIII, Hematol & BMT Unit, Bergamo, Italy
[9] Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[10] Genentech Inc, San Francisco, CA USA
[11] Klinikum Univ Munchen, Dept Internal Med 3, Munich, Germany
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.617.617
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
617
引用
收藏
页数：7
相关论文
共 50 条
  • [21] Acalabrutinib Versus Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia: ASCEND Final Results
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (09) : 2 - 4
  • [22] A match-adjusted indirect treatment comparison of lenalidomide plus rituximab versus rituximab plus chemotherapy for relapsed and/or refractory follicular lymphoma.
    Fox, Christopher P.
    Arcaini, Luca
    Hernandez-Ilizaliturri, Grancisco
    Tabah, Ashley
    Parker, Christopher
    Jones, Jeffrey
    Abouzaid, Safiya
    Watkins, Claire
    Bachy, Emmanuel
    AMERICAN JOURNAL OF HEMATOLOGY, 2019, 94 : S29 - S30
  • [23] Acalabrutinib (Acala) versus idelalisib plus rituximab (IdR) or bendamustine plus rituximab (BR) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): ASCEND final results.
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De La Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric Joseph
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Quah, Cheng Seok
    Jurczak, Wojciech
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [24] Is bendamustine plus rituximab a suitable option for rituximab-refractory duodenal-type follicular lymphoma?
    Cencini, E.
    Fabbri, A.
    Mecacci, B.
    Bocchia, M.
    ACTA GASTRO-ENTEROLOGICA BELGICA, 2020, 83 (03) : 493 - 493
  • [25] ACALABRUTINIB VS IDELALISIB PLUS RITUXIMAB (IDR) OR BENDAMUSTINE PLUS RITUXIMAB (BR) IN RELAPSED/REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): FINAL RESULTS OF ASCEND
    Ghia, Paolo
    Pluta, Andrzej
    Wach, Malgorzata
    Lysak, Daniel
    Kozak, Tomas
    Simkovic, Martin
    Kaplan, Polina
    Kraychok, Iryna
    Illes, Arpad
    De la Serna, Javier
    Dolan, Sean
    Campbell, Philip
    Musuraca, Gerardo
    Jacob, Abraham
    Avery, Eric J.
    Lee, Jae Hoon
    Wang, Denise
    Patel, Priti
    Jurcza, Wojciech
    HAEMATOLOGICA, 2020, 105 : 205 - 206
  • [26] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study In Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Wierda, William G.
    Jones, Jeffrey A.
    Swinnen, Lode J.
    Yang, Jianning
    Cui, Yue
    Busman, Todd
    Krivoshik, Andrew
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2010, 116 (21) : 1019 - 1019
  • [27] Navitoclax (ABT-263) Plus Fludarabine/Cyclophosphamide/Rituximab (FCR) or Bendamustine/Rituximab (BR): A Phase 1 Study in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Kipps, Thomas J.
    Swinnen, Lode J.
    Wierda, William G.
    Jones, Jeffrey Alan
    Coutre, Steven E.
    Smith, Mitchell R.
    Yang, Jainning
    Cui, Yue
    Busman, Todd
    Enschede, Sari
    Humerickhouse, Rod
    BLOOD, 2011, 118 (21) : 1669 - 1669
  • [28] NAVITOCLAX (ABT-263) PLUS FLUDARABINE/CYCLOPHOSPHAMIDE/RITUXIMAB (FCR) OR BENDAMUSTINE/RITUXIMAB (BR): A PHASE 1 STUDY IN PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Kipps, T.
    Swinnen, L.
    Wierda, W.
    Jones, J.
    Coutre, S.
    Smith, M.
    Yang, J.
    Cui, Y.
    Chyla, B.
    Busman, T.
    Enschede, S.
    Humerickhouse, R.
    HAEMATOLOGICA, 2012, 97 : 219 - 219
  • [29] BENDAMUSTINE PLUS RITUXIMAB FOR RELAPSED OR REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA: A RETROSPECTIVE STUDY
    Merchionne, F.
    Quintana, G.
    Minoia, C.
    Guarini, A.
    Galise, I.
    Quarta, G.
    Loseto, G.
    Melpignano, A.
    HAEMATOLOGICA, 2014, 99 : 696 - 697
  • [30] Phase II study with Fludarabine and Cyclophosphamide plus Rituximab (FC plus R) in relapsed follicular lymphoma patients.
    Sacchi, S
    Tucci, A
    Merli, F
    Orsucci, L
    Cervetti, G
    Occhini, U
    Liberati, M
    Tarantini, G
    Callea, V
    Brugiatelli, M
    Lauta, VM
    Baldini, L
    Luminari, S
    Federico, M
    BLOOD, 2002, 100 (11) : 572A - 572A
12345